Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease.

Field JJ, Strunk RC, Knight-Perry JE, Blinder MA, Townsend RR, DeBaun MR
Am J Hematol. 2009 84 (4): 231-3

PMID: 19291727 · DOI:10.1002/ajh.21370

Baseline level of the cysteinyl leukotriene (CysLT), leukotriene E4 (LTE4), is associated with an increased pain rate in children and adults with sickle cell disease (SCD). To provide additional evidence for a role of CysLTs in the pathogenesis of vaso-occlusion, we tested the hypothesis that LTE4 levels will increase within an individual during painful episodes compared to baseline. In a cohort of 19 children and adults with SCD, median LTE4 levels increased from 82.36 pg/mg creatinine at baseline to 162.81 pg/mg creatinine during a painful episode (P < 0.001). These data further support a contribution of CysLTs to the process of vaso-occlusion.

Copyright 2009 Wiley-Liss, Inc.

MeSH Terms (25)

Acetates Adolescent Adult Anemia, Sickle Cell Anti-Asthmatic Agents Asthma beta-Thalassemia Biomarkers Child Cohort Studies Female Fetal Hemoglobin Hemoglobin C Disease Heterozygote Hospitalization Humans Ischemia Leukotriene Antagonists Leukotriene E4 Male Pain Quinolines Retrospective Studies Sickle Cell Trait Young Adult

Connections (2)

This publication is referenced by other Labnodes entities: